APD-356 (Arena)
Jandacek, R.J.
Current Opinion in Investigational Drugs 6(10): 1051-1056
2005
ISSN/ISBN: 1472-4472 PMID: 16259227 Document Number: 586893
Arena is developing APD-356, the lead in a series of orally active, small-molecule 5-hydroxytryptamine 2C agonists for the potential treatment of obesity and diabetes. A phase IIb trial was initiated in June 2005, and preliminary results were expected at the end of 2005.